FGFR4 and hepatocellular carcinoma: Recently, the BLU554 (fisogatinib) phase I trial showed that gatekeeper (Val550) and hinge-1 (Cys552) residues in the kinase domain of FGFR4 were identified mutations in two HCC patients treated with BLU55422.